At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
PF-06946860drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF-06946860 IN PATIENTS WITH CANCER AND CACHEXIA
In Brief
A Phase 1 clinical trial evaluating PF-06946860 for Cachexia and 3 related conditions. Completed, enrolled 11 participants across 10 sites.
Detailed Summary
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartNov 2020
Primary CompletionMar 2022
TodayJul 2026
First PostedMar 6, 2020
Enrollment StartNov 17, 2020
Primary CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.3 years ago
Interventions
PF-06946860drug
subcutaneous injection